Biden Administration Proposal to abolish the Trump-era model It links the medicines and biological products in Part B of Medicare with the lowest prices received by pharmaceutical manufacturers in other wealthy countries.
is called Most-favored-nation model, The initiative matches the payment of Medicare Part B drugs with the lowest price paid by any country in the Organization for Economic Cooperation and Development whose per capita GDP accounts for at least 60% of U.S. per capita GDP. The goal of the model is to control the increase in drug prices. The focus of the model is about 50 drugs, which account for a high proportion of medical insurance expenditures.
In the rules proposed by the Center for Medicare and Medicaid Services released on Friday, the agency announced plans to cancel the model. CMS states that it has received approximately 1,166 letters related to the model. Almost all commenters agree that the high cost of prescription drugs needs to be addressed, but most people also expressed concern about launching the model during the Covid-19 pandemic.
CMS stated: “If finalized, our proposal will allow us to take time to further consider the issues raised by the commenters and will resolve it by repealing the procedural flaws of the November 2020 interim final rule.”
The most-favoured-nation model came into effect through the provisional final rules issued on November 27, 2020. The rule was originally scheduled to take effect from January 1 this year to December 31, 2027. But the rule and the model have never been implemented.
In December 2020, four lawsuits related to provisional final rules and models were filed. A federal judge issued a national preliminary injunction in one of the lawsuits, banning the rule from taking effect as expected on January 1.
The supplier also made it clear that it opposed the rule. In November last year, Anders Gilberg, Senior Vice President of Government Affairs of the Medical Group Management Association, said, The model will be cut off Payments to medical practices that are treating some of the most vulnerable patients in the United States. Later, the American Hospital Association urged CMS Withdraw immediately Provisional final rules, and “replaced by serious efforts to reform drug pricing.”
In addition, the supplier claimed that the agency did not follow proper procedures when releasing the model.
The supplier foretells that CMS proposes to cancel the model.
“We have long opposed mandatory and untested models,” Gilberg of MGMA said in an email. “When this model was first announced last year, we were puzzled that the ultimate responsibility for solving the country’s high drug prices lies with medical groups, not pharmaceutical companies. If this model goes into effect, it will threaten some of the country’s most vulnerable. Of patients have access to care.”
CMS is now exploring new opportunities to address the high cost of Medicare Part B drugs, manufacturer’s pricing, and the consequent increase in Medicare drug expenditures.
The agency stated in its statement: “We will continue to carefully consider the comments we received in the interim final rule in November 2020, as we are exploring the inclusion of value in medical insurance Part B drug payments and improving beneficiaries’ access to evidence-based care All options.” The latest proposed rule.
Photo: z_wei, Getty Images
